October 6, 2023 07:30 AM EDTUpdated 04:08 PM
People
Deals

Ab­cam lays out de­tails be­hind $5.7B Dana­her ac­qui­si­tion, takeover at­tempts by founder and for­mer CEO

Katherine Lewin

News Reporter

UK-based Ab­cam re­vealed more de­tails be­hind its $5.7 bil­lion ac­qui­si­tion by Dana­her, in­clud­ing the dozens of po­ten­tial buy­ers the com­pa­ny en­gaged …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times